reports
Rhythm Pharmaceuticals Announces Publication of Results from Phase 2 S...
Rhythm Pharmaceuticals Announces Publication of Results from Phase 2 Study of Setmelanotide for the Treatment of Hypothalamic Obesity in The Lancet Diabetes & Endocrinology - Publication highlights administration of setmelanotide therapy resulted in a mean percent reduction in BMI of 15% at 16 weeks and 26% at one year of treatment - - Topline data from ongoing pivotal Phase 3 clinical trial in hypothalamic obesity on track for 2Q 2025 - BOSTON, April 29, 2024 (GLOBE NEWSWIRE) -- Rhythm Pharmaceuticals, Inc. (Nasdaq: RYTM), a global commercial-stage biopharmaceutical company focused on...
Streamline Health® Reports Fiscal Fourth Quarter and Full Year 2023 Fi...
Streamline Health® Reports Fiscal Fourth Quarter and Full Year 2023 Financial Results 14% growth of SaaS revenue in fiscal 2023 compared to fiscal 2022$0.4 million of adjusted EBITDA generated in the fourth quarter of fiscal 2023 compared to ($0.2 million) during the fourth quarter of fiscal 2022; $2.4 million of adjusted EBITDA improvement in fiscal 2023 vs. fiscal 2022($1.4 million) net loss during the fourth quarter of fiscal 2023, compared to ($2.2 million) during the fourth quarter of fiscal 2022$15.0 million of Booked SaaS ACV as of January 31, 2024; $15.6 million of Booked SaaS ACV a...
Streamline Health® Expands eValuator™ Footprint With Existing Client
Streamline Health® Expands eValuator™ Footprint With Existing Client Following an efficient implementation process, a leading Florida-based healthcare provider is expanding its footprint and utilization of eValuator Atlanta, GA, April 29, 2024 (GLOBE NEWSWIRE) -- (NASDAQ: STRM), a leading provider of solutions that enable healthcare providers to improve financial performance, announced that it has expanded its existing contract with a 1,250 bed, Epic-based academic medical center serving central Florida. The health system recently completed its initial implementation of eValuator and ha...
Cidara Therapeutics Announces Presentations Highlighting Phase 1 and P...
Cidara Therapeutics Announces Presentations Highlighting Phase 1 and Phase 2a Clinical Data on CD388 at ESCMID 2024 SAN DIEGO, April 26, 2024 (GLOBE NEWSWIRE) -- Cidara Therapeutics, Inc. (Nasdaq: CDTX), a biotechnology company using its proprietary Cloudbreak® platform to develop drug-Fc conjugate (DFC) immunotherapies designed to save lives and improve the standard of care for patients facing serious diseases, today announced two poster presentations highlighting data on CD388 at the 34th European Society of Clinical Microbiology and Infectious Diseases (ESCMID) conference, being held A...
Fuel Tech Schedules 2024 First Quarter Financial Results and Conferenc...
WARRENVILLE, Ill.--(BUSINESS WIRE)-- Fuel Tech, Inc. (NASDAQ: FTEK), a technology company providing advanced engineering for the optimization of combustion systems, emissions control and water treatment in utility and industrial applications, today announced that it will issue its financial results for the first quarter ended March 31, 2024 on Tuesday, May 7, 2024 after the close of the stock market. Management will host a conference call on Wednesday, May 8, 2024 at 10:00 am ET / 9:00 am CT to discuss the results and business activities. Interested parties may participate in the call by dia...
Cannae Holdings, Inc. Announces First Quarter 2024 Earnings Release Da...
LAS VEGAS--(BUSINESS WIRE)-- Cannae Holdings, Inc. (NYSE: CNNE) (“Cannae” or the “Company”) today announced that the Company will release its first quarter 2024 financial results after the market close on Thursday, May 9, 2024. The Company will also hold a conference call to discuss its financial results at 5:00 pm (Eastern Time) on the same day. The conference call can be accessed by dialing 1-844-826-3035 (domestic) or 1-412-317-5195 (international) and asking for the Cannae Holdings First Quarter 2024 Earnings Call. A telephonic replay will be available at the conclusion of the call and c...
Streamline Health® Signs Second Enterprise Client
Streamline Health® Signs Second Enterprise Client 700-Bed health system adds eValuator™, becomes second healthcare provider leveraging both eValuator and RevID to improve revenue integrity pre-bill Atlanta, GA, April 25, 2024 (GLOBE NEWSWIRE) -- (NASDAQ: STRM), a leading provider of solutions that enable healthcare providers to improve financial performance, announced that it has expanded its partnership with a 5 facility, 700-bed Oracle EHR based health system. The system has been using RevID’s automated charge reconciliation for more than 2 years and has elected to add eValuator’s c...
Cidara Therapeutics Reacquires Global Development and Commercial Right...
Cidara Therapeutics Reacquires Global Development and Commercial Rights to CD388 and Announces Private Placement Financing of $240 Million - $240 million private placement financing led by RA Capital Management with significant participation by Bain Capital Life Sciences as well as BVF Partners and Canaan Partners to fund Phase 2b clinical trial - CD388, which is active against all strains of influenza A and B, is being developed for pre-exposure prophylactic treatment - Company to host business strategy update conference call and webcast today at 4:30 PM ET ...
Rhythm Pharmaceuticals to Report First Quarter 2024 Financial Results ...
Rhythm Pharmaceuticals to Report First Quarter 2024 Financial Results on Tuesday, May 7, 2024 BOSTON, April 24, 2024 (GLOBE NEWSWIRE) -- Rhythm Pharmaceuticals, Inc. (Nasdaq: RYTM), a commercial-stage biopharmaceutical company focused on transforming the lives of patients and their families living with rare neuroendocrine diseases, today announced that it will host a live conference call and webcast at 8:00 a.m. ET on Tuesday, May 7, 2024 to report its first quarter 2024 financial results and provide a corporate update. To access the live conference call, participants may register . Wh...
Cidara Therapeutics Announces Divestiture of Rezafungin to Mundipharma...
Cidara Therapeutics Announces Divestiture of Rezafungin to Mundipharma* to Focus on Advancing the Clinical Development of Cloudbreak DFC Pipeline Transaction provides company with an estimated approximately $128 million in cost savings, including approximately $67 million in clinical development and CMC costs over the next three years and an additional approximately $61 million in forecasted obligations through the patent life of rezafungin Cidara to further focus on advancing Cloudbreak development programs, including a planned IND filing for its lead oncology candidate, CBO421, as well a...
Retail Opportunity Investments Corp. Reports 2024 First Quarter Result...
Retail Opportunity Investments Corp. Reports 2024 First Quarter Results SAN DIEGO, April 23, 2024 (GLOBE NEWSWIRE) -- Retail Opportunity Investments Corp. (NASDAQ:ROIC) announced today financial and operating results for the three months ended March 31, 2024. HIGHLIGHTS $11.0 million of net income attributable to common stockholders ($0.09 per diluted share)$37.9 million in Funds From Operations (FFO)(1) ($0.28 per diluted share)FFO per diluted share guidance for 2024 reaffirmed ($1.03 - $1.09 per diluted share)5.7% increase in same-center cash net operating income (1Q‘24 vs. 1Q...
Cidara Therapeutics Provides Corporate Update and Reports Fourth Quart...
Cidara Therapeutics Provides Corporate Update and Reports Fourth Quarter and Full Year 2023 Financial Results SAN DIEGO, April 22, 2024 (GLOBE NEWSWIRE) -- Cidara Therapeutics, Inc. (Nasdaq: CDTX) (the Company), a biotechnology company using its proprietary Cloudbreak® platform to develop drug-Fc conjugate (DFC) immunotherapies designed to save lives and improve the standard of care for patients facing serious diseases, today reported financial results for the fourth quarter and full year ended December 31, 2023 and provided an update on its corporate activities and product pipeline. “...
Cidara Therapeutics Announces Receipt of Nasdaq Delinquency Notice
Cidara Therapeutics Announces Receipt of Nasdaq Delinquency Notice SAN DIEGO, April 22, 2024 (GLOBE NEWSWIRE) -- Cidara Therapeutics, Inc. (Nasdaq: CDTX) (the Company), a biotechnology company using its proprietary Cloudbreak® platform to develop drug-Fc conjugate (DFC) immunotherapies designed to save lives and improve the standard of care for patients facing serious diseases, announced on April 17, 2024, that the Company received a notice from the Listing Qualifications Staff of The Nasdaq Stock Market LLC (Nasdaq) advising the Company that its failure to timely file its Annual Report o...
Capital Bancorp, Inc. Reports First Quarter 2024 Results
Capital Bancorp, Inc. Reports First Quarter 2024 Results Net Income of $6.6 million, or $0.47 per share. Net Income, as adjusted(1) of $7.1 million, or $0.51 per shareROAA of 1.15% and ROAE of 10.19% for 1Q 2024Adjusted Metrics(1) excluding Merger-Related Expenses: ROAA of 1.24% and ROAE of 11.03% for 1Q 2024 Loan Growth of $61.2 million, or 12.9% annualized for 1Q 2024Deposit Growth of $109.7 million; Noninterest bearing deposits increased $48.4 million, or 7.8% from 4Q 2023Cash dividend of $0.08 per share declared ROCKVILLE, Md., April 22, 2024 (GLOBE NEWSWIRE) -- Capital Bancorp, Inc....
Streamline Health® To Report Fourth Quarter and Fiscal Year 2023 Finan...
Streamline Health® To Report Fourth Quarter and Fiscal Year 2023 Financial Performance Atlanta, GA, April 22, 2024 (GLOBE NEWSWIRE) -- (“Streamline” or the “Company”) (Nasdaq: STRM), a leading provider of solutions that enable healthcare providers to proactively address revenue leakage and improve financial performance, today announced that it will release its financial results for the three and twelve month periods ended January 31, 2024 on Monday April 29, 2024 after the close of the financial markets. The Company will conduct a conference call on Tuesday, April 30, 2024, at 9:00 AM E...
Cidara Therapeutics Announces Reverse Stock Split
Cidara Therapeutics Announces Reverse Stock Split SAN DIEGO, April 22, 2024 (GLOBE NEWSWIRE) -- Cidara Therapeutics, Inc. (Nasdaq: CDTX) (the Company), a biotechnology company using its proprietary Cloudbreak® platform to develop drug-Fc conjugate (DFC) immunotherapies designed to save lives and improve the standard of care for patients facing serious diseases, today announced that the Company effected a reverse stock split of its issued and outstanding common stock, at a ratio of 1-for-20. The effective time of the reverse stock split will be 5 p.m. ET on April 23, 2024. The Company’s co...
Catalyst Pharmaceuticals to Report First Quarter 2024 Financial Result...
Catalyst Pharmaceuticals to Report First Quarter 2024 Financial Results on May 8, 2024 The Company will Host a Conference Call and Webcast on Thursday, May 9, 2024, at 8:30 AM ET CORAL GABLES, Fla., April 22, 2024 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. (“Catalyst” or “Company”) (Nasdaq: CPRX), a commercial-stage biopharmaceutical company focused on in-licensing, developing, and commercializing novel medicines for patients living with rare and difficult-to-treat diseases, today announced that it will release its first quarter 2024 financial results after the market close on W...
Interface Commits to Absolute Emission Reduction Efforts to Solve Clim...
ATLANTA--(BUSINESS WIRE)-- Interface, Inc. (NASDAQ: TILE), the global flooring solutions company and leader in sustainability, today announced it is focusing on direct carbon reduction and carbon storage to meet the urgency of the climate crisis. The company is aligning its strategy to meet its climate commitments, which do not allow for carbon offsets. The planet is at an inflection point and absolute emission reductions are critical to solving the climate crisis. Beginning in 2025, Interface will repurpose former offset investments to accelerate innovation projects that will result in dire...
- Wedbush Research
UBI UBISOFT ENTERTAINMENT SA
VMW VMWARE INC. CLASS A
WTFC WINTRUST FINANCIAL CORPORATION
WDC WESTERN DIGITAL CORPORATION
TTWO TAKE-TWO INTERACTIVE SOFTWARE INC.
TRIP TRIPADVISOR INC.
SIMON SILICON MOTION TECHNOLOGY CORPORATION SPONSORED ADR
PSTG PURE STORAGE INC. CLASS A
NVDA NVIDIA CORPORATION
NTAP NETAPP INC.
MU MICRON TECHNOLOGY INC.
INTC INTEL CORPORATION
IMAX IMAX CORPORATION
GOOGL ALPHABET INC. CLASS A
GME GAMESTOP CORP. CLASS A
EXPE EXPEDIA GROUP INC.
EWBC EAST WEST BANCORP INC.
CNK CINEMARK HOLDINGS INC.
CFG CITIZENS FINANCIAL GROUP INC.
AXTI AXT INC.
AMC AMC ENTERTAINMENT HOLDINGS INC. CLASS A
DHI D.R. HORTON INC.
7974 NINTENDO CO. LTD.
2330 TAIWAN SEMICONDUCTOR MANUFACTURING CO. LTD.
2303 UNITED MICROELECTRONICS CORP.
EA ELECTRONIC ARTS INC.
HPE HEWLETT PACKARD ENTERPRISE CO.
ARGX ARGENX ADS
AMD ADVANCED MICRO DEVICES INC.
AAPL APPLE INC.
MSFT MICROSOFT CORPORATION
BKNG BOOKING HOLDINGS INC.
AVGO BROADCOM INC.
DELL DELL TECHNOLOGIES INC CLASS C
SMCI SUPER MICRO COMPUTER
U INC.
ABNB UNITY SOFTWARE
PLTK AIRBNB INC. CLASS A
RBLX PLAYTIKA HOLDING
MRVL ROBLOX
STX MARVELL TECHNOLOGY INC
APP SEAGATE TECHNOLOGY HLDGS PLC
GFS APPLOVIN CORP
YOU GLOBALFOUNDRIES INC
DDI CLEAR SECURE INC
SKLZ DOUBLEDOWN INTERACTIVE CO LTD
EMBRAC B SKILLZ INC
EMBRACER GROUP AB
- Michael Pachter
- Nick McKay
TTWO TAKE-TWO INTERACTIVE SOFTWARE INC.
GOOGL ALPHABET INC. CLASS A
GME GAMESTOP CORP. CLASS A
7974 NINTENDO CO. LTD.
EA ELECTRONIC ARTS INC.
AAPL APPLE INC.
MSFT MICROSOFT CORPORATION
U UNITY SOFTWARE
PLTK PLAYTIKA HOLDING
RBLX ROBLOX
APP APPLOVIN CORP
DDI DOUBLEDOWN INTERACTIVE CO LTD
SKLZ SKILLZ INC
EMBRAC B EMBRACER GROUP AB
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.